Matthew J Ellis Selected Research

Aromatase Inhibitors

1/2022	Evaluation of Sensitivity to Endocrine Therapy Index (SET2,3) for Response to Neoadjuvant Endocrine Therapy and Longer-Term Breast Cancer Patient Outcomes (Alliance Z1031).
10/2021	Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early-Stage Breast Cancer.
1/2021	RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer.
1/2020	Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α.
1/2020	Immune Checkpoint Profiles in Luminal B Breast Cancer (Alliance).
1/2020	Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohort.
1/2020	ESR1 Mutations Are Not a Common Mechanism of Endocrine Resistance in Patients With Estrogen Receptor-Positive Breast Cancer Treated With Neoadjuvant Aromatase Inhibitor Therapy.
1/2020	Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action.
10/2019	Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer.
10/2018	Comprehensive Profiling of DNA Repair Defects in Breast Cancer Identifies a Novel Class of Endocrine Therapy Resistance Drivers.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Matthew J Ellis Research Topics

Disease

165	Breast Neoplasms (Breast Cancer) 01/2022 - 05/2002
112	Neoplasms (Cancer) 01/2022 - 05/2002
14	Triple Negative Breast Neoplasms 01/2022 - 01/2010
11	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2004
6	Disease Progression 01/2018 - 07/2006
5	Pathologic Complete Response 11/2017 - 03/2009
3	Carcinogenesis 11/2020 - 01/2014
3	Carcinoma (Carcinomatosis) 01/2020 - 08/2005
3	Osteoporosis 07/2017 - 04/2013
3	Diarrhea 04/2016 - 08/2005
2	Hypersensitivity (Allergy) 01/2021 - 01/2020
2	Squamous Cell Carcinoma of Head and Neck 01/2021 - 10/2014
2	Metabolic Bone Diseases (Osteopenia) 07/2017 - 04/2013
2	Fatigue 04/2016 - 04/2009
2	Exanthema (Rash) 04/2016 - 08/2005
1	Inflammation (Inflammations) 08/2021
1	Intraoperative Complications 01/2021

Drug/Important Bio-Agent (IBA)

67	Estrogen ReceptorsIBA 01/2022 - 08/2003
36	Hormones (Hormone)IBA 10/2021 - 08/2003
35	Aromatase InhibitorsIBA 01/2022 - 08/2003
26	Proteins (Proteins, Gene)FDA Link 12/2021 - 05/2009
23	Anastrozole (Arimidex)FDA LinkGeneric 10/2021 - 12/2006
22	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2003
21	Estrogens (Estrogen)FDA Link 01/2021 - 08/2003
19	Phenobarbital (Luminal)FDA Link 04/2021 - 08/2007
18	Tamoxifen FDA LinkGeneric 01/2020 - 05/2002
18	Letrozole (Femara)FDA LinkGeneric 01/2020 - 05/2002
15	Fulvestrant (Faslodex)FDA Link 01/2022 - 09/2009
13	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 08/2007
13	Progesterone Receptors (Progesterone Receptor)IBA 01/2020 - 08/2003
11	exemestane (Aromasin)FDA Link 10/2021 - 12/2006
11	RNA (Ribonucleic Acid)IBA 01/2021 - 12/2009
10	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2004
9	Biological ProductsIBA 11/2020 - 10/2003
9	Pharmaceutical PreparationsIBA 11/2019 - 08/2005
7	ErbB Receptors (EGF Receptor)IBA 08/2021 - 08/2005
7	Phosphotransferases (Kinase)IBA 01/2021 - 01/2004
7	Estradiol (Delestrogen)FDA LinkGeneric 01/2020 - 08/2009
7	Paclitaxel (Taxol)FDA LinkGeneric 06/2015 - 05/2004
6	AnthracyclinesIBA 01/2020 - 10/2007
5	Estrogen Receptor alphaIBA 12/2021 - 05/2004
5	ProteomeIBA 08/2017 - 12/2013
5	Peptides (Polypeptides)IBA 03/2016 - 08/2003
5	ParaffinIBA 11/2015 - 11/2010
5	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2013 - 05/2004
4	neratinibIBA 01/2022 - 04/2009
4	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2021 - 11/2015
4	Aromatase (CYP19)IBA 01/2020 - 07/2009
4	palbociclibIBA 01/2020 - 11/2015
4	Formaldehyde (Formol)FDA Link 08/2015 - 11/2010
3	Tyrosine Kinase InhibitorsIBA 01/2022 - 04/2009
3	LigandsIBA 12/2021 - 09/2011
3	NVP-BKM120IBA 12/2020 - 03/2011
3	taxaneIBA 01/2020 - 03/2009
3	Messenger RNA (mRNA)IBA 01/2020 - 01/2017
3	Long Noncoding RNAIBA 12/2018 - 01/2014
3	Tyrosine (L-Tyrosine)FDA Link 01/2018 - 04/2005
3	MK 2206IBA 11/2017 - 08/2013
3	Phosphatidylinositols (Phosphatidylinositol)IBA 11/2013 - 08/2004
3	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 08/2013 - 10/2007
3	Doxorubicin (Adriamycin)FDA LinkGeneric 08/2011 - 05/2004
2	Everolimus FDA Link 01/2021 - 03/2011
2	AntigensIBA 01/2020 - 01/2018
2	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2020 - 12/2014
2	CateninsIBA 01/2020 - 02/2016
2	human ERBB2 proteinIBA 07/2018 - 04/2012
2	CytokinesIBA 01/2018 - 12/2014
2	Phosphoric Monoester Hydrolases (Phosphatases)IBA 01/2018 - 08/2004
2	MA 12 (MA12)IBA 01/2018 - 08/2012
2	Goserelin (Zoladex)FDA Link 11/2017 - 08/2017
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2015 - 04/2012
2	AntibodiesIBA 10/2014 - 08/2011
2	Fluorouracil (Carac)FDA LinkGeneric 12/2013 - 04/2012
2	Epirubicin (Ellence)FDA LinkGeneric 12/2013 - 04/2012
2	temsirolimus FDA Link 05/2013 - 11/2012
2	TOR Serine-Threonine KinasesIBA 05/2013 - 03/2011
2	thiamine triphosphorate (TTP)IBA 11/2012 - 03/2007
2	Irinotecan (Camptosar)FDA LinkGeneric 04/2012 - 06/2011
2	Lapatinib (GW572016)FDA Link 08/2005 - 04/2005
2	LipidsIBA 08/2004 - 08/2003
1	HM781-36BIBA 01/2022
1	ChemokinesIBA 08/2021
1	Carboplatin (JM8)FDA LinkGeneric 08/2021
1	Interferon-gamma (Interferon, gamma)IBA 08/2021
1	Docetaxel (Taxotere)FDA Link 08/2021
1	Antiviral Agents (Antivirals)IBA 01/2021
1	Therapeutic UsesIBA 01/2021
1	Immune Checkpoint ProteinsIBA 01/2021

Therapy/Procedure

104	Therapeutics 01/2022 - 01/2003
22	Drug Therapy (Chemotherapy) 01/2022 - 01/2004
13	Adjuvant Chemotherapy 01/2021 - 05/2004
11	Neoadjuvant Therapy 08/2021 - 04/2004
3	Immunotherapy 01/2020 - 01/2017
3	Segmental Mastectomy (Lumpectomy) 06/2011 - 01/2007
2	Precision Medicine 12/2021 - 01/2016
2	Catheters 01/2021 - 07/2013
2	Aftercare (After-Treatment) 12/2017 - 06/2011
2	Transplantation 09/2013 - 09/2006
2	Chemoprevention 11/2004 - 05/2002
1	Patient Readmission 01/2021